Omeros (NASDAQ:OMER) Releases Earnings Results, Beats Estimates By $0.17 EPS

Omeros (NASDAQ:OMER) released its earnings results on Monday. The biopharmaceutical company reported ($0.54) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.71) by $0.17, RTT News reports. During the same quarter last year, the firm earned ($0.15) earnings per share.

Omeros Trading Down 3.0 %

Shares of Omeros stock opened at $8.22 on Tuesday. Omeros has a twelve month low of $2.61 and a twelve month high of $13.60. The stock has a market cap of $476.35 million, a price-to-earnings ratio of -3.56 and a beta of 2.03. The company has a fifty day moving average price of $8.66 and a 200 day moving average price of $7.58.

Analyst Ratings Changes

A number of research firms have weighed in on OMER. StockNews.com downgraded shares of Omeros from a “hold” rating to a “sell” rating in a research note on Friday, March 21st. D. Boral Capital reaffirmed a “buy” rating and issued a $36.00 target price on shares of Omeros in a research report on Tuesday. Finally, Needham & Company LLC reissued a “hold” rating on shares of Omeros in a research report on Friday, January 17th. One research analyst has rated the stock with a sell rating, two have given a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Omeros currently has an average rating of “Moderate Buy” and a consensus target price of $22.50.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.